clostridia strain formulation VE303
Term · Oncology and biomedicine · MLC-T-ONC-012652
An orally bioavailable formulation composed of eight nonpathogenic, nontoxigenic, commensal strains of Clostridia derived from healthy human stool samples and manufactured from clonal cell banks, for the potential prevention of recurrent Clostridium difficile (C. difficile) infections. Upon oral administration of the Clostridia strain formulation VE303, the microbiota populates the gastrointestinal (GI) tract. The transplanted microbiota allows re-population of the patient's microbiome with diverse protective microorganisms that competitively exclude C. difficile. This may prevent recurrent C. difficile infections.
| Identifier | MLC-T-ONC-012652 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | bacterial strain formulation VE303; live biotherapeutic product VE303 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012652",
"term": "clostridia strain formulation VE303",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable formulation composed of eight nonpathogenic, nontoxigenic, commensal strains of Clostridia derived from healthy human stool samples and manufactured from clonal cell banks, for the potential prevention of recurrent Clostridium difficile (C. difficile) infections. Upon oral administration of the Clostridia strain formulation VE303, the microbiota populates the gastrointestinal (GI) tract. The transplanted microbiota allows re-population of the patient's microbiome with diverse protective microorganisms that competitively exclude C. difficile. This may prevent recurrent C. difficile infections.",
"synonyms": [
"bacterial strain formulation VE303",
"live biotherapeutic product VE303"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/clostridia-strain-formulation-ve303/"
}
Record 4,991 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.